186 related articles for article (PubMed ID: 12176593)
1. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients.
Lietz K; John R; Schuster M; Ankersmit J; Burke E; Suciu-Foca N; Edwards N; Mancini D; Itescu S
Transplant Proc; 2002 Aug; 34(5):1828-9. PubMed ID: 12176593
[No Abstract] [Full Text] [Related]
2. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients.
Teebken OE; Strüber M; Harringer W; Pichlmaier MA; Haverich A
Transplant Proc; 2002 Jun; 34(4):1265-8. PubMed ID: 12072335
[No Abstract] [Full Text] [Related]
3. Histopathological findings in heart transplant patients under tacrolimus-mycophenolate mofetil versus cyclosporine microemulsion-azathioprine.
Sgrosso JL; Ferrer J; Araujo G; Romeo L; Parisi C; Vázquez MC
Transplant Proc; 2002 Feb; 34(1):115-6. PubMed ID: 11959214
[No Abstract] [Full Text] [Related]
4. Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy.
Sánchez V; Delgado JF; Blasco T; Dalmau R; Morales JM; Escribano P; Tello R; Hernández J; Velázquez T; Sotelo T; Gómez-Sánchez MA; Sáenz de la Calzada C
Transplant Proc; 1999 Sep; 31(6):2515-6. PubMed ID: 10500695
[No Abstract] [Full Text] [Related]
5. Anti-T-cell-antibody prophylaxis in children: success with a novel combination strategy of mycophenolate mofetil and antithymocyte serum.
Boucek MM; Pietra B; Sondheimer H; Luna M; Shaffer E; Hall P; Campbell D
Transplant Proc; 1997 Dec; 29(8A):16S-20S. PubMed ID: 9414669
[No Abstract] [Full Text] [Related]
6. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.
Fischer L; Sterneck M; Gahlemann CG; Malago M; Rogiers X; Broelsch CE
Transplant Proc; 2000 Nov; 32(7):2125-7. PubMed ID: 11120098
[No Abstract] [Full Text] [Related]
7. Improved survival after lung transplantation in patients treated with tacrolimus/mycophenolate mofetil as compared with cyclosporine/azathioprine.
Izbicki G; Shitrit D; Aravot D; Sulkes J; Saute M; Sahar G; Kramer MR
Transplant Proc; 2002 Dec; 34(8):3258-9. PubMed ID: 12493439
[No Abstract] [Full Text] [Related]
8. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.
Fabrega AJ; Corwin CL; Hunsicker L
Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634
[No Abstract] [Full Text] [Related]
9. One and a half years of experience with mycophenolate mofetil (Cellcept) in cardiac transplantation: a prospective, randomized study.
Seebacher G; Weigel G; Griesmacher A; Mallinger R; Zuckermann A; Grimm M; Laufer G
Transplant Proc; 1999 Dec; 31(8):3291-3. PubMed ID: 10616480
[No Abstract] [Full Text] [Related]
10. A pilot study of cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H
Transplant Proc; 2000 Dec; 32(8):2778. PubMed ID: 11134800
[No Abstract] [Full Text] [Related]
11. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
Transplant Proc; 1999; 31(1-2):1131-2. PubMed ID: 10083505
[No Abstract] [Full Text] [Related]
12. Tolerability of mycophenolate mofetil in organ transplant recipients.
Schweizer RT; Meisterling LD
Transplant Proc; 2001 May; 33(3):2309. PubMed ID: 11377540
[No Abstract] [Full Text] [Related]
13. Improvement in long-term graft survival in cadaveric renal transplant recipients treated with mycophenolate mofetil.
Hazzan M; Provot F; Glowacki F; Copin MC; Roumilhac D; Labalette M; Pruvot FR; Noel C
Transpl Int; 2004 Oct; 17(9):525-30. PubMed ID: 15338120
[TBL] [Abstract][Full Text] [Related]
14. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy.
Weber M; Deng S; Arenas J; Aradhye S; Grossman R; Shaw L; Naji A; Barker C; Brayman KL
Transplant Proc; 1997 Dec; 29(8):3669-70. PubMed ID: 9414883
[No Abstract] [Full Text] [Related]
15. Triple therapy with mycophenolate mofetil versus azathioprine.
Muñiz ML; Amenabar J; Gómez-Ullate P; Urbizu J; Lampreabe I
Transplant Proc; 1999; 31(1-2):1144-6. PubMed ID: 10083512
[No Abstract] [Full Text] [Related]
16. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.
Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033
[No Abstract] [Full Text] [Related]
17. Selective CellCept therapy in high-risk renal transplant recipients.
Isenberg A; Singh TP; Shen GK; Freed BM; Conti DJ
Transplant Proc; 1998 Jun; 30(4):1188-9. PubMed ID: 9636480
[No Abstract] [Full Text] [Related]
18. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil.
Kimball JA; Pescovitz MD; Book BK; Norman DJ
Transplantation; 1995 Dec; 60(12):1379-83. PubMed ID: 8545860
[TBL] [Abstract][Full Text] [Related]
19. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.
Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T
Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil in ongoing chronic kidney allograft dysfunction.
Senn B; Rochat P; Schwarzkopf AK; Weinreich T; Binswanger U
Transplant Proc; 1998 Dec; 30(8):4075-6. PubMed ID: 9865301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
